CannaPharmaRX, Inc.
CPMD
$0.00
$0.000.00%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 404.62% | 5,175.97% | 4,278.29% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 404.62% | 5,175.97% | 4,278.29% | -- | -- |
| Cost of Revenue | 202.39% | 365.01% | 379.32% | 5,657.32% | 5,620.83% |
| Gross Profit | -150.16% | -234.83% | -250.70% | -4,407.16% | -4,447.57% |
| SG&A Expenses | 19,764.71% | -22.19% | -53.26% | -51.99% | -100.07% |
| Depreciation & Amortization | -880.90% | -228.95% | -129.81% | -100.08% | -102.99% |
| Other Operating Expenses | -49.00% | -49.00% | -49.00% | -49.00% | -3.47% |
| Total Operating Expenses | 223.51% | 207.98% | 123.13% | 182.07% | -68.34% |
| Operating Income | -179.68% | -125.24% | -67.43% | -130.02% | 74.50% |
| Income Before Tax | -630.59% | -1,001.72% | 116.92% | -368.56% | 118.41% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -630.59% | -1,001.72% | 116.92% | -368.56% | 118.41% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -630.59% | -1,001.72% | 116.92% | -368.56% | 118.41% |
| EBIT | -179.68% | -125.24% | -67.43% | -130.02% | 74.50% |
| EBITDA | -152.27% | -212.76% | -103.13% | -190.32% | 77.51% |
| EPS Basic | -179.49% | -37.70% | 108.78% | -477.78% | 85.77% |
| Normalized Basic EPS | 54.30% | 67.88% | 108.99% | -187.88% | 2.58% |
| EPS Diluted | -179.49% | -37.70% | 108.78% | -477.78% | 85.77% |
| Normalized Diluted EPS | 54.30% | 67.88% | 108.99% | -187.88% | 2.58% |
| Average Basic Shares Outstanding | 30.64% | 59.53% | 103.05% | 87.39% | 77.86% |
| Average Diluted Shares Outstanding | 30.64% | 59.53% | 103.05% | 87.39% | 77.86% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |